About this research groupThis research group is a cross-disciplinary research collaboration of four Radboudumc groups, with the aim of advancing clinical translation for colorectal cancer.
It is our mission to improve the outcome of patients with CRC, to enlarge our understanding of CRC biology, and to educate researchers and clinicians at all levels of their careers. Our innovative collaboration of cancer biologists, pharmacologists, pathologists, and medical oncologists enables purposeful research that goes from molecules to cells and to the patient, and vice versa.
We focus our translational research on new treatment paradigms: novel targets, improved treatment regimes, and synergistic combination strategies. Our specific expertise includes targeted therapy, regimen optimization, drug development, pharmacology, pathology, biomarkers, microbiota, and the tumour immune microenvironment.
By combining our strengths, we aim to break new ground in overcoming patient-specific drug resistance and immune evasion mechanisms; to develop and test individual therapy combinations in patient-derived 3D models; and to translate our findings into the clinic. We believe this cross-disciplinary approach can significantly improve CRC treatment efficacy while reducing adverse effects.
This collaborating research group is led by multiple researchers.
This research is led by Daniele Tauriello (Cell Biology).
TiMElabIn the Tumour Immune MicroEnvironment lab, we study immune evasion in the colorectal cancer metastatic microenvironment. We think that a better understanding of the cancer ecosystem will allow the normalization of the corrupted tumour milieu, boosting anti-tumour immunity.
Our ambition is to contribute to fundamental understanding, using innovative cancer models (mouse and human) to perform purposeful research that goes from molecules to cells and to the patient. Therefore, we have a strong focus on translational research, aiming to develop novel targets, improved treatment regimes, and synergistic combination strategies. This is only possible in the context of interdisciplinary collaborations, both at the Radboudumc and with outside partners.
This research is led by Nielka van Erp (Pharmacy).